Timothy C. Fong

Biography

 Tim Fong joined the executive team March 16, 2017. Tim has over 20 years of biotech industry experience with broad expertise in therapeutic drug discovery and development. Tim has led teams in discovery research, preclinical studies, product characterization, and GMP manufacturing process development in several platform technologies, including cell and gene therapy, bio-active peptides and recombinant protein with a focus on cancer immunotherapy, angiogenesis, autoimmunity, and inflammatory diseases. He has held positions of increasing responsibility at Chiron (Novartis), Aventis Gencell, Sangstat (Genzyme), BD Biosciences, Progenitor Cell Therapy (NeoStem), and Cellerant. Tim earned his doctorate in Immunology from the Department of Microbiology & Immunology, UCLA School of Medicine, and completed postdoctoral fellowships at the Salk Institute in La Jolla, CA, and at UC San Diego. Tim also holds an MBA from St. Mary’s College, CA. He is a past member of the Product and Process Development and Immunotherapy Committees, International Society for Cell Therapy, and a member of the American Association of Cancer Research, American Society for Hematology, American Association of Immunologists, and Society for Immunotherapy of Cancer.

Research Interest

Cell and gene therapy, Immunotherapy